Table 1.
Baseline Characteristics of HIV-Infected Patients Who Were Dispensed Antiretroviral Therapy in an Outpatient Setting Within Kaiser Permanente Northern California (2004–2010) and the Veterans Aging Cohort Study (2004–2012)
| Characteristic | Overall (n = 10 083) | Veterans Aging Cohort Study (n = 7984) | Kaiser Permanente Northern California (n = 2099) |
|---|---|---|---|
| Median follow-up (months, IQR) | 5.29 (2.14–12.0) | 4.75 (1.94–12.0) | 9.53 (2.99–12.0) |
| Age (n, %) | |||
| Median age (years, IQR) | 48.0 (40.0–55.0) | 49.0 (42.0–56.0) | 43.0 (37.0–50.0) |
| 18–50 years | 5686 (56.4%) | 4151 (52.0%) | 1535 (73.1%) |
| 50–59 years | 4397 (43.6%) | 3833 (48.0%) | 564 (26.9%) |
| Female sex (n, %) | 511 (5.1%) | 248 (3.1%) | 263 (12.5%) |
| Race (n, %) | |||
| White | 3973 (39.4%) | 2942 (36.8%) | 1031 (49.1%) |
| Black or African American | 4972 (49.3%) | 4573 (57.3%) | 399 (19.0%) |
| Asian/Native Hawaiian/Other Pacific Islander | 200 (2.0%) | 81 (1.0%) | 119 (5.7%) |
| American Indian/Alaska Native | 53 (0.5%) | 37 (0.5%) | 16 (0.8%) |
| Unknown/Multiracial | 885 (8.8%) | 351 (4.4%) | 534 (25.4%) |
| Hispanic (n, %) | 939 (9.3%) | 546 (6.8%) | 393 (18.7%) |
| Unknown | 467 (4.6%) | 0 (0%) | 467 (22.2%) |
| Body mass index ≥30 kg/m2 (n, %) | 1659 (17.3%) | 1275 (16.2%) | 384 (22.1%) |
| Unknown | 473 (4.7%) | 108 (1.4%) | 365 (17.4%) |
| Viral hepatitis coinfection (n, %) | |||
| Hepatitis Ba | 326 (3.2%) | 241 (3.0%) | 85 (4.0%) |
| Hepatitis Cb | 1825 (18.1%) | 1636 (20.5%) | 189 (9.0%) |
| History of alcohol dependence/abuse (n, %) | 2368 (23.5%) | 1980 (24.8%) | 388 (18.5%) |
| Diabetes mellitus (n, %) | 929 (9.2%) | 805 (10.1%) | 124 (5.9%) |
| Cancer (n, %) | 643 (6.4%) | 509 (6.4%) | 134 (6.4%) |
| Heart failure (n, %) | 189 (1.9%) | 169 (2.1%) | 20 (1.0%) |
| Median HIV viral load (log10 copies/mL, IQR) | 4.7 (4.2–5.2) | 4.8 (4.2–5.2) | 4.6 (4.1–5.1) |
| Missing (n, %) | 333 (3.3%) | 84 (1.1%) | 249 (11.9%) |
| CD4 cell count (n, %) | |||
| Median (cells/mm3, IQR) | 244 (119–354) | 237 (110–350) | 265 (160–368) |
| <200 cells/mm3 | 3971 (40.0%) | 3307 (41.8%) | 664 (33.0%) |
| 200–500 cells/mm3 | 4999 (50.4%) | 3884 (49.1%) | 1115 (55.4%) |
| ≥500 cells/mm3 | 950 (9.6%) | 717 (9.1%) | 233 (11.6%) |
| Missing | 163 (1.6%) | 76 (1.0%) | 87 (4.1%) |
| Median ALT (IU/mL, IQR) | 29 (20–43) | 29 (20–44) | 28 (20–41) |
| Missing (n, %) | 744 (7.4%) | 353 (4.4%) | 391 (18.6%) |
| Calendar year of ART initiation, n (%) | |||
| 2004–2006 | 3967 (39.3%) | 3139 (39.3%) | 828 (39.4%) |
| 2007–2009 | 3511 (34.8%) | 2549 (31.9%) | 962 (45.8%) |
| 2010–2012 | 2605 (25.8%) | 2296 (28.8%) | 309 (14.7%) |
Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid.
aHepatitis B virus infection defined by ever-positive hepatitis B surface antigen.
bHepatitis C virus infection defined by ever-positive hepatitis C virus antibody or hepatitis C virus RNA.